Market news

Alcon has seen its share price grind lower in recent years, which naturally puts a spotlight on whether the current valuation still lines up with what the business earns. For anyone tracking the stock, the core question is whether the recent price level reflects a fair read of Alcon's earnings power. The share price has declined 26.8% over the past 5 years, which puts real pressure on the idea that the current market value is in step with the earnings the company produces. The business model...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.

PUEBLO, Colo., September 04, 2026--UBS today announced that Financial Advisors Caitlin Alcon, Calvin Mason, and Craig Cisney will be joining the firm. They will be joining the UBS Mountain West Market, managed by Mitch Markley, and will report to Market Director Justin French.

Alcon stock reacts to US Medicaid drug pricing agreement New US Medicaid drug pricing agreements involving Alcon (SWX:ALC) and eight other healthcare companies have put the stock in focus for investors assessing potential implications for its eye care drug portfolio. At around CHF58.30 per share, Alcon has seen short term share price pressure related to the Medicaid headlines, with the 1-day share price return down 0.44% and the year-to-date share price return down 8.25%. In contrast, the...

Alcon, a global leader in eye care, announced that TÜV SÜD has certified the Clareon® Monofocal intraocular lens (IOL) for MDR compliance. This certification is supported by clinical evidence, including more than 30 peer-reviewed publications demonstrating the Clareon® Monofocal IOL's ability to deliver sharp, clear distance vision along with functional intermediate visual acuity.1 Alcon is currently updating the Clareon Monofocal IFU to reflect the extended claim for depth of focus for intermed

GENEVA, August 26, 2026--Alcon Prices EUR 500 Million Senior Notes Offering

Alcon (ALC) said late Wednesday it priced a public offering of 500 million euros ($582.6 million) of

Sustainable Growth Advisers (SGA), an investment management company, released its second-quarter 2026 investor letter for its “Global Growth Strategy.” The letter can be downloaded here. The SGA Global Growth Portfolio returned 7.4% gross and 7.2% net, compared with 14.9% for the MSCI ACWI and 19.8% for the MSCI ACWI Growth Index. Momentum leadership and enthusiasm around […]

Pershing Square Holdings, an investment holding company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. Pershing Square is an alternative asset manager that primarily manages capital in publicly traded investment vehicles, with 98% of its capital structure dedicated to such assets, including Howard Hughes Holdings. This capital […]

Detailed price information for Alcon Inc (ALC-N) from The Globe and Mail including charting and trades.

Alcon stock presents a clear valuation split right now. The intrinsic value estimate from a Discounted Cash Flow (DCF) approach points to a large upside gap, while earnings-based market multiples lean expensive and the share price has still delivered a 16.5% decline over the past 5 years. Over the past 5 years, Alcon has delivered a 16.5% decline, which raises the bar for any valuation case that argues the stock is now attractively priced. Recent news around Alcon's partnership with RxSight...

Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight’s proprietary light-adjustable technology, which allows eye surgeons to […]

Higher equipment and ocular-health profitability allowed Alcon to raise guidance despite recording a $402 million program-discontinuation charge.

ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.

Motley Fool Press Release.

Investing.com -- Alcon lifted its full-year profit guidance late Monday and lowered its estimate for the annual tariff impact to $40 million to $90 million, from a prior range of $100 million to $150 million, factoring in an anticipated refund of around $60 million from the U.S. government.

Tipranks Press Release.

Why Alcon’s latest earnings matter for shareholders Alcon (SWX:ALC) has just reported second quarter 2026 results that combine higher sales with lower profits, giving investors fresh numbers to reassess how the eye care specialist is currently performing. The company reported quarterly sales of US$2.78b and revenue of US$2.82b, compared with US$2.58b and US$2.60b a year earlier, while net income for the first half of 2026 declined to US$189m from US$526m. See our latest analysis for...

GENEVA, August 10, 2026--New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Alcon (ALC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Investors need to pay close attention to ALC stock based on the movements in the options market lately.

Aravind Eye Care System and Alcon, Global Leader in Eye Care today announced the launch of the Aravind Alcon Global Centre of Excellence (CoE) for Vitreoretinal Surgery Training in Coimbatore. Building on the successful launch of the Global Cataract Centre of Excellence in 2024, the new Centre marks the second phase of Aravind & Alcon's Partnership to address one of the most critical gaps in global eye care – access to retina training. The dedicated Vitreoretinal Centre of Excellence will streng

Vancouver, British Columbia--(Newsfile Corp. - July 20, 2026) - Platauro Metals Corp. (TSXV: PURO) (formerly "Mexican Gold Mining Corp.") ("Platauro" or the "Company") is pleased to announce the successful completion of the previously announced plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement") pursuant to the arrangement agreement dated April 8, 2026 (the "Arrangement Agreement"), whereby Platauro acquired all of the issued and outstanding common...

ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.